US 12059497

I'll verify the current record for US 12,059,497 against USPTO and CAFC sources before summarizing.

US 12,059,497 — Verified Summary

Verification note up front. I re-ran targeted searches against USPTO-hosted/derived records (PatentCenter data mirrored via Google Patents and DrugPatentWatch), the PACER-derived D.N.J. dockets, and CAFC 2026 docket material. Everything below marked [verified] was read in a retrieved source; [unverified] marks items I could not confirm.

1. Bibliographic record

Note on expiry discrepancy (do not reconcile silently): Google Patents states an adjusted expiration of 2037-05-12, while DrugPatentWatch and the Hong Kong patent-journal family listing state 2036-10-15. The ten-month delta is consistent with patent term adjustment/extension, but I could not retrieve the face-of-patent term-adjustment field to confirm. Use 2036-10-15 as the statutory-base date and 2037-05-12 as the adjusted date reported by Google Patents.

2. Abstract (verbatim) [verified]

"Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient."

3. Plain-language overview of the independent claims

Independent claim 1 — a composition claim. In ordinary language:

A refrigerated-shelf-stable injectable liposomal irinotecan product, in which the drug is present as an irinotecan–sucrose octasulfate (SOS) salt trapped inside small, single-membrane ("unilamellar") lipid vesicles made of cholesterol plus one or more phospholipids. The composition must meet four numeric/functional requirements at the same time:

1. Drug loading: 500 g ± 10% of irinotecan (measured as the free-anhydrous-base "moiety") per mole of total liposome phospholipid — i.e., a high drug-to-lipid ratio;
2. Salt stoichiometry: a gram-equivalent ratio of irinotecan to SOS of 0.85 to 1.2 — i.e., the drug and the sulfate trapping agent are near stoichiometric balance;
3. pH: the composition is at pH ~7.25–7.5 at room temperature before storage; and
4. Stability result: after the first 6 months at 2–8 °C, the composition contains less than 20 mol % lyso-phosphatidylcholine (lyso-PC) relative to total phospholipids.

The novelty is not the liposome itself (that platform is old and is the subject of the patentee's earlier patents); it is the combination of a high drug:lipid load, a near-stoichiometric irinotecan:SOS ratio, an elevated pre-storage pH, and a resulting low phospholipid-hydrolysis rate during refrigeration.

Number and identity of other independent claims — [unverified]. The claim set is reported to run to 51 claims. I verified the text of claim 1 (quoted in the D.N.J. complaint analysis and consistent with the "Embodiment" list in the patent specification). I could not verify from the face of the patent how many additional independent claims exist. The dependent-claim pattern described in earlier sections of this analysis (concentration ranges; DSPC/cholesterol/MPEG-2000-DSPE specifics; HEPES/NaCl buffer; extended lyso-PC ceilings at 9/12/24 months; residual TEA/DEA caps; tighter gram-equivalent ranges) is consistent with either a single independent claim (1) with dependents 2–51 or two independent claims with two dependent trains. Confirm against USPTO PatentCenter (application 17/208,042) before relying on this.

Dependent-claim families (as reported by prior analysis; treat as [unverified] as to exact numbering): DSPC + PEG-phospholipid identification; DSPC:cholesterol ≈ 3:2; DSPC 6.1–7.5 mg/mL, cholesterol 2–2.4 mg/mL, MPEG-2000-DSPE 0.11–0.13 mg/mL; molecular-weight/size ≈ 110 nm; HPLC quantification method; 9-, 12-, and 24-month lyso-PC ceilings; residual TEA/DEA below 100 ppm, below ~79 ppm, and below 20 ppm; HEPES 4.05 mg/mL + NaCl 8.42 mg/mL; histidine buffer alternative; gram-equivalent sub-ranges down to ~0.99–1.0; and < 1 mg/mL lyso-PC.

What claim 1 conspicuously does not recite (carried over from the prior-obviousness section): the specification's "Stability Ratio" (SR = irinotecan load ÷ sulfate-group concentration), which the specification treats as critical, and the residual-TEA ceiling. Those appear only in dependent claims. This makes claim 1 materially broader than the specification's central teaching.

4. USPTO and CAFC docket check for this number specifically

AIA trials (PTAB): none on US 12,059,497. I searched for IPRs, PGRs, and CBMs naming 12,059,497, including 2025–2026 filings. Zero proceedings found. The live IPR activity in this corporate family targets US 11,344,552 — not this patent:

• IPR2025-00505 — CSPC Pharmaceutical Group Ltd., CSPC Ouyi Pharmaceutical Co., Ltd. & Conjupro Biotherapeutics, Inc. v. Ipsen Biopharm Ltd., on US 11,344,552, filed 2025-01-17, instituted 2025-08-14.
• IPR2025-01531 — Apotex Inc. v. Ipsen Biopharm Ltd., on US 11,344,552; joinder granted by Paper 16 entered March 12, 2026, joining Apotex to IPR2025-00505 as a "silent understudy." (This is a 2026 PTAB development I located; it is on the '552 patent, not the '497 patent.)

CAFC 2026 dockets: no appeal invoking 12,059,497 was identified. Searches of Federal Circuit 2026 appellate material returned nothing naming this patent. The closest 2026 CAFC material I retrieved concerns unrelated patents (e.g., Appeal No. 2024-1520 on US 7,679,637). Because the D.N.J. case has not reached judgment, no appeal could yet lie — so an absence of CAFC activity is expected rather than exculpatory.

District court (the only identified assertion of this patent):

• Ipsen Biopharmaceuticals, Inc. et al. v. Conjupro Biotherapeutics, Inc., et al., D.N.J. 1:24-cv-08723-RMB-MJS, filed 2024-08-23, § 271(e)(2)(A) over NDA No. 218923. Consolidated into 1:24-cv-04991 by order entered 2024-10-18, and administratively terminated. [verified]
• Consolidated action 1:24-cv-04991 (Judge Bumb; Magistrate Judge Skahill) remains pending; third-party litigation tracking shows it last updated August 3, 2026, with no terminal date and no merits disposition recorded. [verified]
• Defendants filed declaratory-judgment counterclaims of invalidity and non-infringement of the '59,497 patent and affirmative defenses under §§ 101, 102, 103 and 112, plus prosecution history estoppel. [verified]

5. Two identifier collisions you must control for

1. 12,059,497 vs. 9,339,497 — both are called "the '497 patent" in the same litigation. In the D.N.J. pleadings, "the '497 patent" refers to U.S. 9,339,497 (one of the nine patents in the original 24-4991 complaint), while 12,059,497 is consistently written "the '59,497 patent." I did not auto-correct either. Any docket-derived research that says "the '497 patent" is almost certainly not talking about 12,059,497. [verified]
2. 11,369,597 ("the '597 patent") is a third, separate patent in the same case and is asserted separately. The IPRs target 11,344,552, yet a fourth number.

6. Uncertainties and stale-data flags

• Date inconsistency in my instructions. The task header states the current date is April 26, 2026, while the session metadata states 2026-09-28. Retrieved third-party records carry "Last Updated" stamps of August 3, 2026 and July 19, 2026 — i.e., later than the task-header date. I have not resolved this; treat any "as of" statement accordingly.
• I could not retrieve the face-of-patent claim set. Claim 1 is quoted in a third-party complaint analysis that faithfully reproduces the claim language; the numbering of claims 2–51 and the existence of any further independent claim are not verified. Pull the printed claims from USPTO PatentCenter (application 17/208,042).
• No merits ruling, no institution decision, no FWD, and no Federal Circuit opinion exists on 12,059,497 as of the latest records I retrieved. The patent is entirely unadjudicated on validity and infringement.
• The Google Patents litigation link for this record (/litigation/New Jersey District Court/case/1:24-cv-08723) matches the docket above; no other district, no ITC § 337 investigation, and no foreign assertion of this U.S. patent was identified.
• EPO note (different office, same family): an EPO Board of Appeal decision surfaced for a related Ipsen liposomal-irinotecan method-of-treatment patent (T 240098), concerning co-administration timing/dosing claims. That is a different patent and a different office; I flag it only so it is not misread as activity on 12,059,497.

7. Bottom line

US 12,059,497 is a Ipsen Biopharm–owned (originally Merrimack) continuation patent, filed 2021-03-22 with a 2015-10-16 priority date and issued 2024-08-13, covering a storage-stabilized liposomal irinotecan sucrose-octasulfate composition characterized by ~500 g irinotecan/mol phospholipid, an irinotecan:SOS gram-equivalent ratio of 0.85–1.2, a pre-storage pH of ~7.25–7.5, and < 20 mol % lyso-PC after 6 months at 2–8 °C. It is asserted in exactly one proceeding — the consolidated D.N.J. ANDA action 1:24-cv-04991 — which was pending as of the most recent docket data retrieved (August 2026). There are no PTAB proceedings and no CAFC 2026 dockets naming this patent, and its claim set is untested. Be careful with the "'497" shorthand: in this docket that shorthand belongs to 9,339,497, not to this patent.

I'll search litigation databases for cases specifically asserting US 12,059,497. Let me run several targeted queries in parallel.

Good — the D.N.J. case is confirmed. Let me check for any additional cases (other defendants, other jurisdictions) and the current case status.

Let me do a final check for any other case in a different jurisdiction or against a different defendant.

Litigation Involving U.S. Patent No. 12,059,497

Bottom line: Searching specifically for the identifier 12,059,497 / US 12,059,497 B2 returns exactly one U.S. litigation — a Hatch‑Waxman (ANDA/505(b)(2)) action in the District of New Jersey, now consolidated under Docket 1:24‑cv‑04991. I found no other district court case, no ITC investigation, and no Federal Circuit appeal naming this patent. I have excluded results for neighboring numbers (US 9,339,497, US 11,344,552, US 12,364,691, US 10,456,360, US 10,993,914) and flag them below only as context.

The one U.S. case asserting the '497 patent

Procedural timeline (verified)

• 2015‑10‑22 — FDA approves Onivyde® (irinotecan liposome injection) under NDA 207793 (Ipsen).
• 2024‑04‑15 — Ipsen files the first action, 24‑4991, asserting eight patents (the '213, '497, '473, '162, '442, '724, '795, and '597 patents). Note: the '59,497 patent had not yet issued at this point. (In the counterclaim pleadings, "the '497 patent" in the initial Notice Letter refers to U.S. 9,339,497, a different patent.)
• 2024‑08‑13 — US 12,059,497 B2 issues.
• 2024‑08‑23 — Ipsen files 24‑8723, asserting only the '497 patent.
• 2024‑08‑28 — Defendants waive service; answers due 2024‑10‑28.
• 2024‑09‑05 — FDA lists the '497 patent in the Orange Book against NDA 207793.
• 2024‑10‑18 — Consolidation order (Docket 12 in 24‑8723). Critically, it carves out a patent‑specific schedule for the '497 patent: Defendants' non‑infringement and invalidity contentions and L. Pat. R. 3.6(c)–(f) document production due November 4, 2024; Ipsen's infringement contentions, responses to invalidity contentions, and L. Pat. R. 3.6(g)–(i) production due December 19, 2024.
• Post‑consolidation — Defendants answered, denying infringement and pleading affirmative defenses including non‑infringement (First Defense) and invalidity under §§ 101, 102, 103 and/or 112 (Second Defense), plus failure to state a claim, prosecution history estoppel, § 288 cost limitation, and equitable defenses. They also filed counterclaims for declaratory judgment of invalidity and/or non‑infringement of the '497 patent.

Cases that do NOT involve the '497 patent (excluded, listed to prevent confusion)

These appear in the same family/litigation campaign but assert different patents — I verified the numbers literally:

No PTAB proceeding names the '497 patent, and no § 315(e)(2) estoppel from any IPR attaches to it.

Non‑U.S. proceeding on the European counterpart (flagged, not U.S. litigation)

The '497 patent's European family member, EP 3,362,049 B1 ("Stabilizing Camptothecin Pharmaceutical Compositions," Ipsen Biopharm; granted July 9, 2025), is under EPO opposition. Two oppositions were filed in April 2026:

• Teva Pharmaceuticals — opposition dated April 7, 2026 (representative: D Young)
• Graf von Stosch Patentanwaltsgesellschaft — opposition dated April 8, 2026 (representative: Lepthien)

This is an EPO opposition, not U.S. litigation, and it is against the EP counterpart rather than US 12,059,497. I note it because it resolves an item the prior sections left flagged as unverified (the "Apr 7, 2026 opposition date") and because the opponents' prior‑art citations will be directly relevant to the U.S. validity fight.

Verification notes and limits

1. I found no U.S. litigation against any other defendant on the '497 patent — no Apotex, Sandoz, Zydus, Biocon, or other ANDA case is captured asserting this number in the sources retrieved.
2. No Federal Circuit appeal naming the '497 patent was found. Consistent with the prior section, I do not assert one exists. Any appeal could only arise from the pending D.N.J. action or from a PTAB decision on some other patent.
3. No merits outcome exists to report. The case is at the contention/discovery stage on the '497 patent. Any statement of a "result" would be fabrication.
4. Source-date discrepancy to flag: the task date is April 26, 2026, but several aggregator pages retrieved (DrugPatentWatch, IP Verse) carry "last updated" stamps of August–September 2026. I report their content, and I flag that the underlying records are dated later than the nominal current date. Where a page states a status ("Final Written Decision" for IPR2025‑00505), I have marked it unverified against the primary PTAB record.
5. Primary sources to confirm: PACER docket for 1:24‑cv‑08723 (Docket 12 = consolidation order) and 1:24‑cv‑04991 (the operative docket going forward); CourtListener dockets 1:24‑cv‑04991 and 1:24‑cv‑08723; Google Patents legal‑events/Litigation for US12059497B2; and the EPO Register for EP 3,362,049 B1.

Summary table

Only one known litigation involves US 12,059,497.

I'll verify the structured block's "no PTAB activity" default against the public record before finalizing.

The IPR activity I'm finding targets the related '552 patent, not the '497 patent. Let me confirm there's no separate proceeding on the '497 patent and check the litigation context.

One more confirmation pass — checking for any 2026 filings or declaratory-judgment actions targeting the '497 patent itself.

PTAB / AIA Trial Landscape — US 12,059,497 B2

Analyst check performed: The ODP structured block reports zero AIA trial proceedings. I ran independent searches for any IPR, PGR, or CBM naming the '497 patent (including 2025–2026 filings, joinder motions, and Director-review dockets) to confirm the structured block is not stale. I found none. The IPR activity in this family targets a different patent — US 11,344,552 — which I address separately below as context, clearly labeled.

Proceedings overview

There are zero AIA trial proceedings on file against US 12,059,497. The count is 0 IPRs, 0 PGRs, 0 CBMs — no institutions, no denials, no settlements, no FWDs, no Federal Circuit appeals of any Board decision on this patent. The bottom line for a defendant is therefore neither "hardened" nor "narrowed": the patent is completely untested at the PTAB. Every claim is live and unadjudicated, which cuts both ways — Ipsen gets no estoppel benefit, but you get no free invalidity ruling either, and you must build a § 102/§ 103 record from scratch.

Timing caveat: The '497 patent issued 2024-08-13 and the § 315(b) one-year bar runs from service of the infringement complaint. Defendants Conjupro/CSPC waived service in D.N.J. 1:24-cv-08723 on 2024-08-28 (answer originally due 2024-10-28). Depending on how the bar is measured and whether the consolidated 24-4991 complaint is the operative service, the § 315(b) window for those defendants has already closed. That is a real and consequential fact — see the Estoppel section.

Proceedings on US 12,059,497

None. No per-proceeding entries can be provided because no proceeding exists. I will not manufacture numbers, panels, or dispositions.

Adjacent-family context (NOT proceedings on the '497 patent — do not cite these as PTAB rulings on your patent)

These matter to you only as strategic signal, because they show how the same patent owner and the same defendants fight over the same Onivyde® irinotecan-liposome franchise.

IPR2025-00505 — CSPC Pharmaceutical Group Ltd., CSPC Ouyi Pharmaceutical Co., Ltd. & Conjupro Biotherapeutics, Inc. v. Ipsen Biopharm Ltd.

• Patent challenged: US 11,344,552 ("Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin") — not the '497 patent.
• Filed: 2025-01-17
• Status: Instituted (per Apotex's joinder motion, Paper 8: Acting Director ruled on discretionary denial 2025-07-16; Board issued institution decision 2025-08-14, Paper 13). Ipsen had argued § 325(D) and § 314(a) discretionary denial in its POPR, contending the same prior art was already considered during prosecution — the Acting Director declined to discretionarily deny.
• Petition grounds: Obviousness (§ 103) over FOLFIRINOX-based combinations (Conroy, Masi, Ginocchi, Carnevale, Dean, et al.), all claims 1–15. Expert: Mark J. Ratain, M.D.
• Key procedural events: Oral argument reportedly scheduled 2026-05-19 (per paragraphfour.com docket summary). I could not confirm whether an FWD has issued as of today's date — searches surfaced no Final Written Decision. Treat the merits outcome as unknown.
• Defensive value for a '497 defendant: Low-to-moderate. An FWD cancelling '552 claims would not touch '497 validity, and '497 claim 1 is a composition claim with storage-stability/pH/gram-equivalent-ratio limitations that the '552 method claims do not share. But it is a live read on whether the Board buys Ipsen's "unexpected results / low POSA expectation of success in pancreatic cancer" narrative — a narrative Ipsen will recycle against any '497 petitioner.

IPR2025-01531 — Apotex Inc. v. Ipsen Biopharm Ltd.

• Patent challenged: US 11,344,552 — not the '497 patent.
• Filed: ~2025-09-12 (Notice of Filing Date Accorded 2025-09-23, Paper 4)
• Status: Joinder under 35 U.S.C. § 315(c) / 37 C.F.R. § 42.122(b), timely filed within one month of the 2025-08-14 institution of IPR2025-00505. Apotex filed a substantially identical petition, with expert Robert Dreicer, M.D. adopting Dr. Ratain's declaration in toto, and offered to act as a "silent understudy."
• Settlement/termination: None reported.
• Appeal: None.
• Defensive value for a '497 defendant: Confirms the family is under coordinated, multi-party attack — CSPC/Conjupro first, Apotex joining. That pattern is the strongest available predictor that a '497 IPR petition is contemplated or in preparation by a party not yet time-barred.

Strategic summary

Claim status on the '497 patent: every claim 1–51 is UNTESTED. No claim has been canceled, and none has been sustained. For reference, the claim set runs from independent claim 1 (storage-stabilized liposomal irinotecan composition with 500 g ±10% irinotecan moiety/mol total phospholipid; gram-equivalent ratio 0.85–1.2; pH before storage of about 7.25–7.5; <20 mol % lyso-PC after 6 months at 2–8 °C) through dependent claims 2–51, which progressively narrow to DSPC/cholesterol/MPEG-2000-DSPE specifics, TEA/DEA residual limits (claims 17–22, 38–39, 50–51), buffer identity (claims 23–24), and tighter gram-equivalent ranges with specific SEC/HPLC quantitation methodology (claims 31–37, 40–49). I have the claim text only as reproduced by a third-party database (DrugPatentWatch, updated 2026-09-05); I did not verify it against the face of the patent, so confirm claim numbering before serving contentions.

Estoppel landscape is asymmetric — and mostly runs against the other defendants, not you. Because Conjupro/CSPC and Apotex chose to IPR the '552 patent rather than the '497 patent, no § 315(e)(2) estoppel attaches to any ground against the '497 patent. Conjupro/CSPC are free to raise any '497 invalidity theory in the D.N.J. case, and they have — their November 4, 2024 invalidity contentions and their paragraph IV certification expressly cover the '497 patent (they certified it invalid in their Notice Letter and filed DJ counterclaims of non-infringement and invalidity against it). The strategic inversion: for a new defendant not yet served, all prior-art grounds remain open, but the § 315(b) clock has not yet started either — you can file an IPR, whereas the existing D.N.J. defendants may be time-barred from doing so on the '497 patent while still able to fight validity in court.

Pattern signals. Three things stand out. (1) No defensive aggregator — neither Unified Patents nor any similar entity is in the '497 chain; the family challenges are brand-vs-generic, not troll-vs-aggregator. (2) The patent owner is a serial continuation filer defending in layers — Ipsen filed 24-4991 (2024-04-15) over nine patents, then a second suit 24-8723 (2024-08-23) on the '497 patent ten days after it issued, then a third suit 25-13647 (2025-07-22) over the '691 patent. Ipsen litigates new issuances immediately. (3) The defendants are litigating, not staying — Conjupro/CSPC went to the PTAB on '552 but not on '497, which suggests either a deliberate resource allocation or a § 315(b) bar on the newer patent.

Unverified flag: A third-party database (ipverse.greyb.com, last updated 2026-06-11) lists "Stabilizing Camptothecin Pharmaceutical Compositions / IPSEN BIOPHARM / Apr 7, 2026" under a column headed "Opposition Date." This is ambiguous on its face and may be a European Patent Office opposition, not a PTAB proceeding. I could not verify it. Do not treat this as a PTAB filing — but it is worth investigating, because a parallel EPO opposition would give you the opponent's prior-art citations for free.

Recommended next steps

If you are a defendant being asserted on the '497 patent:

1. Do not expect help from the Board — there is none. Because zero IPRs exist on this patent, you cannot point to a canceled claim, an FWD, or a Federal Circuit affirmance as sanction-bait. Any infringement theory Ipsen asserts on claims 1–51 is a theory you must defeat on your own record.
2. Plead and fight invalidity in D.N.J. The operative vehicle for '497 is the consolidated New Jersey action, Ipsen Biopharmaceuticals, Inc. et al. v. Conjupro Biotherapeutics, Inc. et al., D.N.J. 1:24-cv-4991 (into which 1:24-cv-08723 was consolidated and administratively terminated by order dated 2024-10-18; Justia docket for 1:24-cv-08723). Note the disclosed posture defect: the complaint alleges infringement of "one or more claims" with no element-by-element chart, relying solely on the § 271(e)(2)(A) NDA-submission theory.
3. Check your own § 315(b) status before doing anything else. If you were served with a complaint asserting the '497 patent more than one year ago (the existing defendants were served 2024-08-28), you are barred from filing an IPR on it. If you are newly served, you have a one-year runway — and given that the family leaders already burned their shot on '552, an early '497 petition built on the stabilization art (the lyso-PC / phospholipid-hydrolysis and stability-ratio references described at col. 2 of the '497 specification, not the FOLFIRINOX oncology art) could be the first genuinely fresh challenge.
4. Mine the '552 IPR record for estoppel-free ammunition. The petitions and POPRs at ptacts.uspto.gov petition 1557313 are public and contain Ipsen's own positions on pancreatic-cancer POSA expectations and unexpected results. Those admissions are usable against '497 claim 1's pH and storage-stability limitations (claims 1, 7–16, 40–49) — but note the art there is oncology-regimen art, not formulation-stability art, so it will not map cleanly onto the composition claims.
5. Monitor for a late-filed petition. The absence of PTAB activity is a timing signal, not a validity signal: '497 was only actionable from late 2024, and PTAB petitions typically trail service by 6–12 months. Check the PTAB E2E / PTAB Decisions portal and the PTAB E2E system quarterly. If an IPR appears, its institution decision will land ~6 months after filing with a statutory FWD deadline of one year from institution (35 U.S.C. § 316(a)(11)) — the milestones to calendar.
6. Verify the claim text independently. Before relying on any claim number, pull the printed claim set from USPTO PatentCenter (application 17/208,042) rather than a commercial database.

Sources: ODP structured block (canonical, zero proceedings); Google Patents US12059497B2 for bibliographic and litigation links; Justia docket 1:24-cv-08723 for the 2024-10-18 consolidation order; PTAB petition records for IPR2025-00505 / IPR2025-01531 (US 11,344,552) at ptacts.uspto.gov and paragraphfour.com IPR2025-01531 POPR.

I'll research the assignment chain for US 12059497, cross-referencing the patent text with public records.

Let me dig into the assignment records and litigation details.

Let me verify the assignment record specifics and check the IPR/PTAB activity on this patent.

Ownership Analysis — US 12,059,497 B2 ("Stabilizing camptothecin pharmaceutical compositions")

Data-access note (read first). I was unable to complete a live query against the USPTO Assignment Center (https://assignmentcenter.uspto.gov/) within this session's tool limits. Accordingly, I have not verified reel/frame numbers or the correspondent-of-record for this patent, and I will not invent them. What follows is grounded in (a) the Google Patents legal-events record embedded in the authoritative patent text supplied, (b) SEC filings for the Merrimack/Ipsen asset sale (EX-2.1 Asset Purchase and Sale Agreement; PREM14A; Form 10-Q), and (c) PACER/Unified Patents litigation records. Fields I could not confirm are marked not confirmed.

Inventors

All eight named inventors, with the addresses of record on the issued patent:

Pattern notes.

• The application US 17/208,042 was filed 2021-03-22, but it carries a 2015-10-16 priority date (PCT family). So the inventive work was done at Merrimack Pharmaceuticals, Inc. (Cambridge, MA) in/around 2015, and the 2021 filing is a continuation prosecuted by the then-current owner, Ipsen Biopharm Ltd. The inventors were therefore Merrimack employees at the priority date, not at the filing date — they no longer had any ownership interest by 2021.
• Four inventors carry Massachusetts addresses and two carry California addresses. The MA/CA split is consistent with Merrimack's dual-site structure (Cambridge HQ plus a South San Francisco liposome-science group descended from its Hermes Biosciences acquisition), but I could not confirm any individual inventor's site affiliation from the retrieved sources — treat the CA/MA inference as suggestive, not established.
• Unusual pattern present (mild): every named inventor's interests were consolidated into a single corporate assignee that then exited the entire technology line. Merrimack sold the Onivyde/liposomal-irinotecan business and the associated IP in April 2017, wound down R&D, laid off its full-time staff by 2019, and dissolved in 2024 after collecting its last milestone. This is a totality-of-the-asset exit rather than the classic "inventors depart within 12 months and the portfolio is fire-sold," but the practical effect is the same: no inventor has a continuing commercial stake.

Original assignee

Two entities must be distinguished:

• Original assignee (at priority/filing of the family): Merrimack Pharmaceuticals, Inc., a Delaware corporation, Cambridge, Massachusetts; publicly traded (NASDAQ: MACK). Primary line of business: clinical-stage oncology, built around a "network biology" platform. It did ship a product embodying the claims — ONIVYDE® (irinotecan liposome injection), FDA-approved 2015-10-22 in combination with fluorouracil and leucovorin for metastatic pancreatic adenocarcinoma after gemcitabine-based therapy. Merrimack was the pioneer; it also had a marketed-product milestone structure with PharmaEngine (Taiwan rights) and a license to Baxter/Baxalta (now Takeda) for ex-US rights.
• Assignee of record on the issued patent (current): Ipsen Biopharm Ltd. (Wrexham, GB) — a subsidiary of Ipsen S.A. (Paris), a global specialty-care pharmaceutical group. Per Google Patents legal events for this record, US 12,059,497 was reassigned from Merrimack Pharmaceuticals, Inc. to Ipsen Biopharm Ltd. via an assignment recorded 2021-03-22.

Current status of the original assignee, Merrimack: dissolved (not bankrupt). Merrimack completed a shareholder-approved asset sale to Ipsen on 2017-04-03 ($575M upfront plus up to $450M contingent milestones). It retained no R&D operations, laid off all full-time employees by 2019, and — after Ipsen paid the $225M first-line pancreatic-cancer milestone in February 2024 — its board determined it had no remaining milestone-bearing assets and dissolved the company, distributing the cash as a dividend. No Chapter 7 or Chapter 11 filing is evident in the sources retrieved.

Current assignee, Ipsen Biopharm Ltd.: operating / commercially active. It (together with Ipsen Biopharmaceuticals, Inc.) sells ONIVYDE, whose claims this patent covers, and is actively litigating to keep generics off the market.

Assignment timeline

The Assignment Center's own reel/frame fields and correspondent fields were not retrievable in this session; the events below are reconstructed from Google Patents legal-events data plus the underlying SEC and court records. I flag the unverifiable fields explicitly rather than supplying numbers.

1. 2015 (priority filing) — not a recorded assignment; origin of title

• Conveyance: n/a (inventor employment / original application)
• Assignor: the eight named inventors
• Assignee: Merrimack Pharmaceuticals, Inc.
• Correspondent: not confirmed
• Context: internal — the inventions were made by Merrimack employees and title vested in Merrimack at the 2015-10-16 priority date.

2. Executed 2017-01-07; closed 2017-04-03 — Patent Assignment Agreement executed as an exhibit to the Asset Purchase and Sale Agreement (SEC EX-2.1, Merrimack Pharmaceuticals, Inc. — Ipsen S.A.)

• Conveyance: Assignment (asset sale / sale of IP; includes "Form of Patent Assignment Agreement")
• Assignor: Merrimack Pharmaceuticals, Inc. (as Seller, "Seller Group")
• Assignee: Ipsen S.A. and its designated Buyer-Group entity (ultimately Ipsen Biopharm Ltd.)
• Correspondent: not confirmed from the retrieved sources
• Context: acquisition — a negotiated, shareholder-approved sale of the entire oncology commercial business and "all Intellectual Property primarily related to the Commercial Business or the Transferred Products," including "all rights of action… present, past and future rights to sue and collect damages… for any such infringement." This is a genuine corporate M&A transfer to an operating buyer, not a fire-sale or securitization. Note the assignment conveys past and future infringement causes of action, which is precisely what enables Ipsen to sue on this patent today.

3. Recorded 2021-03-22 — Reel/frame not confirmed

• Conveyance: Assignment (inventors' interest)
• Assignor: Drummond, Kirpotin, Hayes, Noble, Kesper, Awad, Moore, O'Brien
• Assignee: Merrimack Pharmaceuticals, Inc.
• Correspondent: not confirmed
• Context: internal — chain-of-title perfection for the newly filed continuation US 17/208,042.

4. Recorded 2021-03-22 — Reel/frame not confirmed

• Conveyance: Assignment
• Assignor: Merrimack Pharmaceuticals, Inc.
• Assignee: Ipsen Biopharm Ltd.
• Correspondent: not confirmed
• Context: acquisition — recordation against the 2021 continuation of the title already transferred in the 2017 asset sale.

Post-grant development (not an assignment): a further continuation, US 18/737,163 filed 2024-06-07 (published US 2025/0000796 A1), remains with the same Ipsen ownership. Google Patents shows the patent Active, adjusted expiration 2037-05-12.

If the Assignment Center in fact shows no separately recorded post-issuance assignment beyond the 2021 entries, that is itself consistent with the reconstruction above: title has been static at Ipsen Biopharm Ltd. since the 2017 acquisition was recorded.

Timeline diagram

timeline
    title Ownership of US 12059497
    2015 : Priority filing by Merrimack Pharmaceuticals
    2017 : Merrimack sells oncology assets to Ipsen
         : Deal closes 3 April 2017
    2021 : Continuation filed 22 March
         : Inventors assign to Merrimack
         : Merrimack assigns to Ipsen Biopharm Ltd
    2024 : Patent issues 13 August
         : Ipsen sues Conjupro 23 August
         : Merrimack dissolves after final milestone

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT.
The only transfer is Merrimack → Ipsen Biopharm Ltd., a manufacturing-and-marketing subsidiary of Ipsen S.A. No "IP / Holdings / Ventures / Licensing" naming, no registered-agent address, no single-purpose LLC. Ipsen ships ONIVYDE, the product embodying claim 1 (e.g., an irinotecan:phospholipid ratio of 500 g irinotecan moiety per mol phospholipid, a gram-equivalent irinotecan:SOS ratio of 0.85–1.2, pH 7.25–7.5 before storage, and <20 mol% lyso-PC after 6 months at 2–8 °C). A party that manufactures and sells the covered product is the definition of an operating company.

2. Known asserter in the chain — NOT PRESENT.
Neither Merrimack Pharmaceuticals, Inc. nor Ipsen Biopharm Ltd. / Ipsen S.A. appears on any published NPE/asserter list (Acacia, Marathon, IV, Wi-LAN, Conversant, Vringo, Pendrell, Round Rock, Spangenberg entities, etc.). Ipsen is a €1.6B+ revenue specialty pharma; its litigation posture is brand-vs-generic, not portfolio monetization.

3. Repeat correspondent across the chain — UNKNOWN / not determinable.
I was unable to retrieve the correspondent-of-record for any recorded assignment, so I can neither confirm nor deny a recurring recording attorney. I am not treating this as a signal. If the chain shows the same large IP-recording firm on both the 2017-era and 2021-era entries, that is expected for a $1B M&A integration and is not probative of NPE behavior — M&A and operating-company patent work is exactly what these firms do.

4. Cascading transfers — NOT PRESENT.
There is a single ownership hop (Merrimack → Ipsen), executed in 2017 and recorded against this continuation in 2021. No chained LLCs, no transfers in rapid succession, no shared correspondent addresses across unrelated assignees.

5. Pre-litigation transfer — NOT PRESENT.
There is no ownership change within six months of the first suit on this patent. The assignment predates litigation by three years. The temporal proximity that does exist is a ten-day gap between grant and suit: the patent issued 2024-08-13 and Ipsen filed the second D.N.J. action asserting it on 2024-08-23 (Case 1:24-cv-08723, Judge Bumb; consolidated into 24-4991 on 2024-10-18). That is ordinary brand-generic behavior — assert the freshly issued Orange Book-listed patent — and involves no transfer, so it does not satisfy the signal.

6. Bankruptcy fire-sale — NOT PRESENT.
Merrimack's exit was a negotiated, shareholder-approved M&A sale (PREM14A; Asset Purchase and Sale Agreement dated 2017-01-07; closing 2017-04-03) for $575M cash plus up to $450M in milestones — plainly not a distressed liquidation. No Chapter 7/11 proceeding appears. Merrimack's 2024 dissolution was a voluntary wind-down after its last milestone was received, with the proceeds distributed as a dividend. Contrast the fact pattern to Kodak/Nortel/Polaroid: here the buyer was a strategic acquirer paying full strategic value.

7. Privateering — NOT PRESENT.
Merrimack did not retain the patents and lease them to an NPE to assert on its behalf. It sold the IP and the accompanying "present, past and future rights to sue" outright to Ipsen and kept only contingent milestone receivables tied to Ipsen's regulatory successes. Merrimack holds no assertion rights and does not appear as a co-plaintiff; the plaintiffs are Ipsen Biopharmaceuticals, Inc. and Ipsen Biopharm Ltd., and the defendants are actual generic competitors (Conjupro Biotherapeutics, CSPC Pharmaceutical Group, CSPC Ouyi) seeking FDA approval of NDA No. 218923.

8. Defensive aggregator — NOT PRESENT.
The chain terminates at Ipsen, an active plaintiff. Not RPX / AST / LOT / Unified / OIN.

Additional context that cuts against an NPE reading: this patent is one of a large, co-asserted brand estate in Ipsen Biopharmaceuticals, Inc. v. Conjupro Biotherapeutics, Inc. (D.N.J. 24-4991, filed 2024-04-15) covering, among others, US 8,329,213; 9,339,497; 9,364,473; 9,452,162; 9,492,442; 9,717,724; 10,980,795; 11,369,597; 8,147,867; 10,456,360; and 10,993,914 — i.e., a product-protecting thicket asserted under 35 U.S.C. § 271(e)(2), the signature of an operating innovator protecting a marketed drug rather than a licensing shop. The defendants have counterattacked, including an IPR (P-TACTS Petition No. 1557313, Conjupro/CSPC) arguing the claims were obvious over references including Conroy, Bayever, Melis, Cantore, and Wainberg — which further confirms a real, contested validity fight between commercial rivals.

Verdict

Operating-company assertion.

The chain is a single, clean M&A transfer — Merrimack Pharmaceuticals, Inc. → Ipsen Biopharm Ltd. — executed 2017-01-07, closed 2017-04-03, and recorded against this continuation 2021-03-22 (reel/frame not confirmed in this session). Ipsen markets ONIVYDE, the FDA-approved product embodying claim 1, and is using the patent under § 271(e)(2) against genuine generic competitors (Conjupro / CSPC) in D.N.J. 24-4991 and 24-8723, not against unrelated operating companies. None of the eight NPE signals is present; the only notable ownership event is the seller's voluntary dissolution in 2024, which is an exit-of-business story, not a patent-troll acquisition.

Verify at: https://assignmentcenter.uspto.gov/ (search patent number 12059497) — specifically to capture the reel/frame and correspondent fields I could not confirm. Cross-reference the underlying transfer at Merrimack's SEC EDGAR filings, Form EX-2.1 to Merrimack's Form 8-K (Asset Purchase and Sale Agreement, including the Form of Patent Assignment Agreement), and the litigation dockets at https://dockets.justia.com/docket/new-jersey/njdce/1:2024cv08723/[553645](/patent/553645) and https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/1%3A24-cv-08723.

I'll research US patent 12059497 and its cited prior art.

I have partial citation data. Let me retrieve the complete citations list, including non-patent literature.

Let me retrieve the complete citation list from the patent's front page (Justia and Google Patents mirrors).

Prior-Art Analysis — US 12,059,497 B2

Important scope note before the analysis. I was able to confirm the patent's identity, bibliographic data, and a partial citation list, but I could not retrieve the complete set of all 86 patent citations or the full non‑patent‑literature list before my research budget ran out. Everything below is tagged as [verified] (read in the fetched document or a citation table) or [unverified/partial] (identifier seen only in a list, description inferred). I have not fabricated any citation, date, or claim mapping. Where I cannot confirm something, I say so.

1. Patent identification

Critical legal consequence of the priority date. Because the effective priority date is 16 October 2015, only material that was publicly available, or US patents/applications effectively filed, before 2015‑10‑16, can be § 102 prior art. This immediately excludes the patent's own family members (see § 4 below), which are commonly owned and share the same inventive entity.

2. The claims being tested (proxy)

The authoritative claim text was not fully captured; what the fetched document provides is the "Embodiment" list (Embodiments 1–23), which typically mirrors the granted claims. [verified as embodiments; unverified as exact claim language] The claim families are:

• Composition claims (Emb. 1–3): storage‑stabilized liposomal irinotecan, pH 7.00–7.50, irinotecan sucrose octasulfate in DSPC/cholesterol/MPEG‑2000‑DSPE unilamellar vesicles, 500 mg (±10%) irinotecan per mmol phospholipid, 4.3 mg/mL, <20 mol % lyso‑PC at 6 months at 4 °C.
• Method‑of‑manufacture claims (Emb. 4–5, 19): loading irinotecan into TEA₈‑SOS trapping‑agent liposomes (sulfate 0.4–0.5 M), extrusion through stacked 0.1 µm membranes.
• Parameter/depends claims (Emb. 6–23): mean size 110 nm by DLS; DSPC 6.1–7.5 mg/mL, cholesterol 2–2.4 mg/mL, MPEG‑DSPE 0.11–0.13 mg/mL; HEPES 2–20 mM; NaCl 130–160 mM; packaged 6.81/2.22/0.12 mg/mL; <100 ppm TEA; ≥98% encapsulation at 6 months.

A reference must disclose all of these limitations to anticipate. None of the cited art below does so on its face — the § 102 risk is concentrated in the broadest composition and manufacturing-step claims.

3. Cited patent documents retrieved (partial list, from Google Patents "Citations (86)")

All entries below were read directly from the citation table on the US12059497B2 / related‑family Google Patents pages. [verified as list entries] Descriptions are the reference's own title/assignee as shown.

The remaining ~70 patent citations (including the US 7xxx/8xxx and US 20xx/xxxxxxx entries listed below) were only partially captured.

Additional US patents appearing in the citation list (numbers, issue date, first‑named inventor only — descriptions not retrieved):
7842676 (2010‑11‑30, Janoff); 7846440 (2010‑12‑07, Schoeberl); 7846473 (2010‑12‑07, Yoshino); 7850990 (2010‑12‑14, Tardi); 7871620 (2011‑01‑18, Benz); 7892554 (2011‑02‑22, Marks); 8067432 (2011‑11‑29, Anderson); 8147867 (2012‑04‑03, Hong); 8329213 (2012‑12‑11, Hong); 8496961 (2013‑07‑30, Hong); 8658203 (2014‑02‑25, Drummond); 8703181 (2014‑04‑22, Hong); 8992970 (2015‑03‑31, Hong); 9339497 (2016‑05‑17, Bayever); 9364435 (2016‑06‑14, Yaworski); 9364473 (2016‑06‑14, Bayever); 9452162 (2016‑09‑27, Bayever); 9492442 (2016‑11‑15, Bayever); 9511155 (2016‑12‑06, Drummond); 9717723 (2017‑08‑01, Hong); 9717724 (2017‑08‑01, Bayever); 9724303 (2017‑08‑08, Hong); 9730891 (2017‑08‑15, Hong); 9737528 (2017‑08‑22, Drummond); 9782349 (2017‑10‑10, Hong); 9895365 (2018‑02‑20, Blanchette); 9931298 (2018‑04‑03, Heath); 10350201 (2019‑07‑16, Hong); 10413510 (2019‑09‑17, Hong); 10456360 (2019‑10‑29, Drummond); 10478428 (2019‑11‑19, Blanchette); 10722508 (2020‑07‑28, Hong); 10980795 (2021‑04‑20, Bayever); 10993914 (2021‑05‑04, Drummond); 11052079 (2021‑07‑06, Hong). [unverified — list entries only]

⚠️ Caution: Several of these (7842676/7850990/8147867/8658203/9737528/10456360/10993914 etc.) appear with Merrimack/Ipsen inventors (Drummond, Kirpotin, Hong, Bayever). These are almost certainly same‑family or commonly‑owned documents, not § 102 prior art (see § 4).

4. Citations that are NOT prior art (family / common ownership)

The following were surfaced as "related" documents but share the priority date, inventive entity, or assignee and therefore are excluded under AIA § 102(b)(2)(C) (common ownership) or are simply the same family:

• WO 2017/066726 A1, US 2018/0296484 A1, US 2020/0069586 A1, US 10,456,360 B2, US 10,993,914 B2, US 2021/0205219 A1, US 2023/0108934 A1, US 2025/0000796 A1, EP 3362049 B1, JP 6941606 B2, CN 108366965 / 114073678 / 114099437 — all Ipsen/Merrimack family, priority 2015‑10‑16. [verified]
• US 11,071,726 B2 (Ipsen, gastric‑cancer combination), US 11,369,597 B2, US 11,344,552 B2, US 11,844,795 B2, AU 2013202947 B2 (Ipsen) — related/commonly owned. [verified]
• US 11,229,602 B2 (Western Univ. Health Sciences, bladder cancer, 2022) and US 11,571,386 B2 (Insmed, continuous liposome manufacture, 2023) are later‑published citing documents, i.e., they cite the 497 family — they are not prior art against it. [verified]

5. Cited non‑patent literature (from the specification body)

These references are cited inside the 497 specification and are the most likely § 102/§ 103 comparators: [verified as in‑spec citations]

• U.S. Pat. No. 4,990,610 — methods of preparing sucrosofate (SOS) salts.
• U.S. Pat. No. 5,783,568 — sulfated/sulfonated/phosphorylated sugars and polyols as trapping agents.
• U.S. Pat. No. 8,147,867 — drug‑encapsulating liposomes and methods of making them.
• U.S. Pat. No. 8,658,203 — liposome compositions for treating brain tumors.
• *Ochi, K., et al., 1980, Chem. Pharm. Bull., v. 28, pp. 638–641* — sulfated sucrose (including sucrose octasulfate).
• *Mui, et al., 1993, Biophys. J., v. 65, pp. 443–453* — entrapped‑volume/loading reference.

6. § 102 mapping — honest assessment

Bottom line: On the retrieved record, no cited reference appears to be a clean § 102 anticipation of any independent claim. The cited art is best characterized as § 102(a)(1) background (camptothecin chemistry, PEG‑liposome technology, gradient loading) and § 103 material. The patent's likely validity hinge is whether the Stability Ratio / lyso‑PC formation rate limitations were non‑obvious over Alza‑type liposomal topoisomerase‑inhibitor art combined with the liposome‑stability art. This is consistent with the fact that in the D.N.J. litigation the invalidity contentions for US 12,059,497 were scheduled separately (Conjupro/CSPC invalidity contentions due 2024‑11‑04). [verified via PACER summary]

7. What I could not confirm (and recommended next steps)

1. The complete 86‑item patent‑citation list — only ~45 identifiers were captured. Retrieve the full list directly from USPTO PatentCenter / Google Patents "Citations" tab for US12059497B2.
2. The exact granted claim text — I used the Embodiment list as a proxy. Pull the printed claims from the patent PDF.
3. The full IDS / "References Cited" list — the front‑page 1449 form gives both patent and non‑patent references; the fetched document truncated this.
4. Examiner/applicant categorizations (X/Y/A) from the corresponding EP/JP/PCT search reports, which indicate which references the examiner considered most material.

Sources: patents.google.com/patent/US12059497B2/en; patents.justia.com/patent/12059497; patents.google.com/patent/US20090285878A1; worldwide.espacenet.com (US2018296484A1); patsnap.com litigation note (Ipsen v. Conjupro/CSPC, D.N.J. 1:24‑cv‑08723).

I'll research the prior art section and cited references for this patent before building the § 103 analysis.

Let me pull the specific prior-art citations listed on this patent's page and any validity challenges.

Obviousness Analysis — U.S. Patent No. 12,059,497 B2

"Stabilizing camptothecin pharmaceutical compositions" (Ipsen Biopharm Ltd.; filed 2021‑03‑22; priority 2015‑10‑16)

Scope note / caveats. This is a technical § 103 analysis, not legal advice or a validity opinion. The "Prior Art" data on the page I was given consists of the prior‑art keywords ("irinotecan, composition, liposomes, lyso, liposome"), the prior‑art date (2015‑10‑16), and the "References Cited"/"Cited By" listings. The full text I was provided is truncated before the reference list, so I cross‑checked the cited references via the page's family and third‑party mirrors (Google Patents, Justia, DrugPatentWatch, FPO, PubChem). Where I could not verify a reference's disclosure directly, I say so. Claim text below is the granted claim set as reproduced by DrugPatentWatch (claims for 12,059,497); verify against the official copy at patents.google.com/patent/US12059497B2/en.

1. The claimed subject matter

Independent claim 1 is a product claim requiring, in combination:

Dependents add: DSPC + PEG‑PE (2–4); DSPC:cholesterol ≈ 3:2 (5); DSPC 6.1–7.5 mg/mL and cholesterol 2–2.4 mg/mL (6); HPLC quantification (7); 9/12/24‑month lyso‑PC ceilings (8–16, 40–49); residual TEA/DEA < 100 ppm (17–22), < 79 ppm (19), < 20 ppm (38–39), 10–20 ppm (51); HEPES 4.05 mg/mL + NaCl 8.42 mg/mL (23); histidine buffer (24); ER sub‑ranges down to 0.99–1.0 (25–37); < 1 mg/mL lyso‑PC (46–47).

Note what claim 1 does not recite: the "Stability Ratio" (SR = A/B) that the specification treats as critical, nor the residual‑TEA ceiling of claims 17–22. The independent claim is therefore materially broader than the specification's central teaching.

2. The prior art of record (as reflected on the page)

The page's "References Cited" includes (per the Justia and family listings) at minimum:

Patent references

• US 8,147,867 B2 — Hong, Drummond, Kirpotin (Hermes Biosciences / Merrimack) — "Liposomes useful for drug delivery." Claim 1: liposomal irinotecan comprising a membrane of an uncharged lipid (cholesterol) and a neutral phospholipid, with entrapped irinotecan and sucrose octasulfate (optionally plus a substituted ammonium compound); claim 7: ≥ 90 % of irinotecan remains encapsulated after 6 months at 2–8 °C. Claim 9 recites substituted‑ammonium structure, incl. triethylammonium. (claims)
• US 8,703,181 B2 / US 8,992,970 B2 / US 2014/0154298 A1 — Hong, Drummond, Kirpotin (Merrimack) — same family. US 2014/0154298 claims: DSPC neutral phospholipid (15); PEG‑DSPE (7–8); HEPES and NaCl aqueous medium (16); "relative amounts of the pharmaceutical entity and the sucrose octasulfate are near the point of stoichiometric equivalency" (11) and "at the point of stoichiometric equivalency" (12); entity + SOS "in the form of a salt" (13); molar ratio drug:lipid ≥ 1.0 (10). (FPO, DrugPatentWatch '181)
• US 7,842,676 (Janoff et al., 2010) — listed among references cited on the '497 page; my searches retrieve it as a liposome/camptothecin‑related Janoff reference, but I have not independently verified its full disclosure, so I do not rely on it below.
• Other cited background: US 5,783,568 and US 5,281,237 (sulfated/sulfonated/phosphorylated polyols and sugars usable as trapping agents); US 4,990,610 (sucrosofate salt preparation); US 8,658,203 (liposomes for brain delivery); US 5,013,556; WO 96/25147; US 6,210,707; US 6,355,268; US 6,465,008.
• Non‑patent literature cited: Ochi et al., Chem. Pharm. Bull. 28:638‑641 (1980) (sucrose octasulfate); Mui et al., Biophys. J. 65:443‑453 (1993) (entrapped volume ≈1.7 L/mol PL); Burke et al. (liposomal stabilization of the camptothecin lactone); Colbern (1998); Tardi (2000); Emerson (2000); Lasic (liposome technology texts).

Critical point on status as art. The '497 patent has an effective date of 2015‑10‑16 (AIA). All of the above published well before 2015‑10‑16, so they are § 102(a)(1) printed‑publication art. Because the family shares inventors (Drummond, Kirpotin) and corporate lineage (Hermes → Merrimack → Ipsen), the common‑ownership safe harbors of § 102(b)(2)(C)/§ 103(c) do not remove this art: those exceptions apply only to § 102(a)(2)/(e)‑type applications, not to granted patents or publications. So the applicant's own earlier liposome patents are fully available as § 103 art.

3. Element‑by‑element mapping — Combination I: US 8,147,867 (and its continuation family)

What is missing from Combination I: an express recitation of (i) storage at pH 7.25–7.5 (the '867 examples run at 6.5, though the disclosed range extends to 7.5) and (ii) the < 20 mol % lyso‑PC at 6 months result limitation. Everything else is disclosed, much of it verbatim.

4. Additional grounds

Combination II — '867 family + the art's recognition that phospholipid hydrolysis to lyso‑PL is pH‑dependent.
The '497 specification itself concedes this was known: "[a] pH of 6.0 or 6.5 is believed to minimize hydrolysis of phosphatidylcholine," and "[t]he hydrolytic decomposition of liposomal … phospholipids is affected by the pH of the composition." The '867 family likewise frames the problem as PL hydrolysis producing lyso‑PC (the Background of US 2018/0110771 and of the '497 family states that hydrolysis of PLs "can lead to the formation of lyso‑phosphatidylcholine"). Once pH is recognized as a result‑effective variable for lyso‑PC generation, adjusting the external buffer within the already‑disclosed 6.0–7.5 window to 7.25 is routine optimization.

Combination III — '867 + US 2014/0154298 / US 8,703,181 (same family) + US 8,992,970 to supply the structural specifics: DSPC as the neutral phospholipid, PEG‑DSPE, HEPES/NaCl, "near/at the point of stoichiometric equivalency," and the salt form of irinotecan/SOS.

Combination IV — for the dependents, no additional art is needed: the concentrations in claim 23 (4.05 mg/mL HEPES ≈ 17 mM; 8.42 mg/mL NaCl ≈ 144 mM) are numerically the '867 storage buffer (5 mM HEPES/144 mM NaCl; 20 mM HEPES/135 mM NaCl), and the DSPC/cholesterol/PEG‑DSPE levels of claims 6/11 map to the 3:2:0.015 molar ratio at 4.3 mg/mL irinotecan.

5. Motivation to combine and reasonable expectation of success

1. Same field, same problem, same authors. All references are directed to the identical problem — a storage‑stable injectable liposomal camptothecin — and share inventors (Drummond, Kirpotin) and assignee lineage. KSR teaches that "any need or problem known in the field … and addressed by the patent can provide a reason" to combine, and that a combination of prior elements to solve a known problem is obvious.
2. Explicit motivation in the art. The '867 family identifies PL hydrolysis/lyso‑PC as the storage‑life limiter and expressly discloses the pH window (6.0–7.5) as the lever for membrane‑lipid stability.
3. Finite, identified, predictable solutions. The claimed pH (7.25–7.5) sits inside the disclosed range; selecting among a small number of candidate pH values within an already‑disclosed window is the paradigm of "obvious to try" (KSR; In re Peterson–type range cases).
4. Predicted effect. A POSA would reasonably expect that changing the aqueous buffer pH — the recognized driving variable for ester hydrolysis — would change the rate of PC→lyso‑PC conversion. The only open question is direction and magnitude, and that is resolved by a handful of routine stability pulls (0, 1, 3, 6, 9 months).
5. Commercial pressure. Extending refrigerated shelf life of an approved injectable (ONIVYDE) is a recognized design incentive.
6. Structural elements are inherent. With ~100 % drug loading of irinotecan into TEA‑SOS liposomes at 500 g/mmol (taught in '867), the ER of the resulting salt is necessarily ≈1 (the '497 specification itself reports ~1.02 by precipitation assay, FIG. 8). Under In re Best / In re Kubin reasoning, a prior‑art composition that necessarily possesses the claimed property renders the property limitation unavailing.

6. The strongest counter‑arguments (patentee side)

These must be understood, because they determine whether the prima facie case is overcome:

1. Teaching away / wrong‑direction art. The reference materials state that pH 6.0–6.5 "minimizes hydrolysis of phosphatidylcholine." If a POSA believed 6.5 was the optimum, moving to 7.25 would be expected to increase, not decrease, lyso‑PC. The '497 specification presents the lyso‑PC reduction at pH > 6.5 as a "surprising" observation, and the data are dramatic (e.g., SR‑dependent reduction from ~36 mol % to < 20 mol % lyso‑PC at 9 months). But note the weakness: '867 does not criticize or discredit pH 7.25–7.5; it affirmatively teaches that "about 6.0 to about 7.5" is suitable. A mere preference for 6.5, without disparagement, generally is not teaching away (In re Fulton; DePuy v. Medtronic).
2. pH alone is insufficient — criticality of the SR. The specification shows that Samples 10 and 11 (pH 7.25/7.5 but SR ≈ 785) still exceeded 20 mol % lyso‑PC at 6 months, and that the '867 working example used 0.643 M TEA‑SOS (SR ≈ 778). So a POSA following the '867 example and only raising pH would not arrive at the claimed composition. The patent frames the reduction as synergistic (SR × pH × residual TEA). This is the patentee's best "unexpected results / criticality" argument, and it is a genuine factual question.
3. Critical range evidence. The specification supplies ranges with in‑range data (SR 942 vs 990 vs 1047; TEA < 20/80/100 ppm), which supports the "criticality" narrative for the dependent claims (17–22, 38–39, 50–51).
4. Absence of pre‑2015 art expressly linking elevated extraliposomal pH to lyso‑PC reduction in irinotecan‑SOS liposomes. If the record lacks a reference that actually teaches or suggests the direction of the pH effect for this system, the case reduces to "obvious to try," which can be defeated where the prior art gives no guidance on which of many parameters controls the outcome.

7. Assessment

• Independent claim 1 — strong prima facie § 103 case. Every structural/parametric element except the pH value and the lyso‑PC result limitation is squarely disclosed in the '867 family. The pH value lies within the range the '867 specification expressly calls suitable for membrane‑lipid stability, and pH is a recognized result‑effective variable for phospholipid hydrolysis. Under KSR's "obvious to try" and "finite number of identified, predictable solutions" framework, the combination of ('867 or '181) with the art's own teaching that PL hydrolysis is pH‑dependent renders claim 1 prima facie obvious. Whether that prima facie case is rebutted by the patentee's showing of an unexpected, opposite‑to‑predicted pH effect and of the SR interaction is a factual dispute that would turn on the strength of the "teaching away" evidence and on whether the observed effect is truly unexpected versus a routine optimization.
• Claims 2–16, 23–37, 40–49 (DSPC/PEG‑PE, 3:2 cholesterol, concentrations, HEPES/NaCl, ER sub‑ranges, extended lyso‑PC ceilings) are highly vulnerable: these features are largely disclosed in '867/'181/'298 or are inherent consequences of the disclosed 500 g/mmol loading at near‑stoichiometric SOS ratios.
• Claims 17–22 and 38–39 (residual TEA/DEA ceilings, including < 20 ppm) are the hardest to invalidate on § 103 alone, because they read on the empirical SR/TEA relationship the patent presents as critical; a challenger would need art teaching the residual substituted‑ammonium ceiling or a strong "routine optimization of a known impurity" argument.
• Structural note relevant to validity risk in the field: because the claimed composition overlaps so heavily with the applicant's own earlier '867 family (which is § 102(a)(1) art not shielded by the common‑ownership exception), the validity of claim 1 is likely to be litigated as an obviousness question about the pH limitation and the functional lyso‑PC limitation, not about the formulation itself. The page flags an active U.S. case in the District of New Jersey (1:24‑cv‑08723) and a worldwide family litigation entry, so this is a live issue.

Bottom line: The most probable § 103 combinations are (1) US 8,147,867 in view of US 8,703,181 / US 8,992,970 / US 2014/0154298, and (2) either of those in view of the art's recognition that liposomal phospholipid hydrolysis to lyso‑PC is pH‑dependent — combined, if needed, with the '867 specification's own statement that pH up to about 7.5 is suitable for liposome membrane‑lipid stability. The motivation is the identical problem (refrigerated shelf‑life/storage stability) attacked by the same inventors and assignee with a known, result‑effective variable, and the expectation of success is at least "obvious to try." Claims 2–16, 23–37 and 40–49 appear the most exposed; claims 17–22 and 38–39 the least.

If you want, I can build a formal claim‑chart (claim 1 limitation‑by‑limitation against the '867 and '181 specifications), or run a separate § 112(a) written‑description/enablement analysis given that claim 1 omits the Stability Ratio the specification calls critical.